Edition:
India

Nuevolution's Nue20798 Shows Positive Effect On Disease Scoring


Thursday, 9 May 2019 

May 9 (Reuters) - Nuevolution Ab (Publ) ::NUEVOLUTION'S BET-BD1 SELECTIVE INHIBITOR AND CANDIDATE COMPOUND, NUE20798, SHOWS POSITIVE EFFECT ON DISEASE SCORING AND BIOMARKER LEVELS IN AN ATOPIC DERMATITIS (ECZEMA) MOUSE MODEL.NUEVOLUTION'S BET-BD1 SELECTIVE INHIBITOR AND CANDIDATE COMPOUND, NUE20798, SHOWS POSITIVE EFFECT ON DISEASE SCORING AND BIOMARKER LEVELS IN AN ATOPIC DERMATITIS (ECZEMA) MOUSE MODEL.SAYS NO NEGATIVE EFFECT WAS OBSERVED ON BLOOD PLATELET COUNT WHEN USING NUEVOLUTION'S SELECTIVE BROMODOMAIN INHIBITOR NUE20798.